Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
Study Identifier:
D8560C00002
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Mar 2025 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years
Requirements Information
Sex
Female & Male
Age
18 - 75 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN2030
- Drug: Placebo
Date
Mar 2025 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 75 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
Trial Locations
Location
Status
Location
Research Site
Birmingham, Alabama, United States, 35249
Status
Not yet recruiting
Location
Research Site
Scottsdale, Arizona, United States, 85259
Status
Not yet recruiting
Location
Research Site
Los Angeles, California, United States, 90095
Status
Not yet recruiting
Location
Research Site
Orange, California, United States, 92868
Status
Not yet recruiting
Location
Research Site
Jacksonville, Florida, United States, 32224
Status
Not yet recruiting
Location
Research Site
Tampa, Florida, United States, 33606
Status
Not yet recruiting